@article {Orbaijrheum.160904, author = {Ana-Maria Orbai and Maarten de Wit and Philip J. Mease and Kristina Callis Duffin and Musaab Elmamoun and William Tillett and Willemina Campbell and Oliver FitzGerald and Dafna D. Gladman and Niti Goel and Laure Gossec and Pil Hoejgaard and Ying Ying Leung and Chris Lindsay and Vibeke Strand and D{\'e}sir{\'e}e M. van der Heijde and Bev Shea and Robin Christensen and Laura Coates and Lihi Eder and Neil McHugh and Umut Kalyoncu and Ingrid Steinkoenig and Alexis Ogdie}, title = {Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016}, elocation-id = {jrheum.160904}, year = {2017}, doi = {10.3899/jrheum.160904}, publisher = {The Journal of Rheumatology}, abstract = {Objective To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS). Methods At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. The updated PsA Core Domain Set was voted on and endorsed by OMERACT participants. Results We conducted a systematic literature review of domains measured in PsA RCT and LOS, and identified 24 domains. We conducted 24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop and breakout groups at OMERACT 2016 in which findings were presented and discussed. The updated PsA Core Domain Set endorsed with 90\% agreement by OMERACT 2016 participants included musculoskeletal disease activity, skin disease activity, fatigue, pain, patient{\textquoteright}s global assessment, physical function, health-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda. Conclusion The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set.}, issn = {0315-162X}, URL = {https://www.jrheum.org/content/early/2017/02/09/jrheum.160904}, eprint = {https://www.jrheum.org/content/early/2017/02/09/jrheum.160904.full.pdf}, journal = {The Journal of Rheumatology} }